Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer.
Alessio CortelliniAntonio D'AlessioSiobhan ClearySebastiano ButiMelissa BersanelliPaola BordiGiuseppe ToniniBruno VincenziMarco TucciAlessandro RussoFrancesco PantanoMarco RussanoLuigia Stefania StucciMaria Chiara SergiMartina FalconiMaria Antonietta ZarzanaDaniele SantiniFrancesco SpagnoloEnrica Teresa TandaFrancesca RastelliFrancesca Chiara GiorgiFederica PergolesiRaffaele GiustiMarco FilettiFrancesca Lo BiancoMarina Chiara GarassinoAndrea BotticelliAlain J GelibterMarco SiringoMarco FerrariRiccardo MarconciniMaria Giuseppa VitaleLinda NicolardiRita ChiariMichele GhidiniOlga NigroFrancesco GrossiMichele De TursiPietro Di MarinoPaola QueiroloSergio BracardaSerena MacriniAlessandro InnoFederica ZorattoEnzo VeltriChiara SpotoMaria Grazia VitaleKatia CannitaAlessandra GennariDaniel Laurence MorgansteinDomenico MallardoLorenzo NibidGiovanna SabareseLeonardo BrunettiGiuseppe PerronePaolo Antonio AsciertoCorrado FicorellaDavid James PinatoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
In this study patients on GLM experienced worse outcomes from immunotherapy, independent of baseline features. Prospective studies are warranted to clarify the relative impact of metformin over a pre-existing diagnosis of T2DM in influencing poorer outcomes in this population.